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Thank you very much for the opportunity to respond to the
letter to the editor concerning our publication: “Hypersensitivity to
antibiotics in patients with cystic fibrosis (CF)” and also thanks to
the authors for pointing out possibly unclear issues.
Relating to the concern of possible over diagnosing drug
hypersensitivity in our study [1] and the comparison to prevalence
rates in different studies [2,3], we carefully evaluated the differing
prevalence rates and came to the conclusion that the study cohorts
were significantly different. Our inclusion criteria, as stated in the
“Methods” section, involved patients who had received more than
three courses of parenteral antibiotic treatment before. Our
observations were also restricted to parenteral treatment courses
for feasibility on the one hand and on the other hand because this
group of patients is mostly affected by the problem [4].
Accordingly only few children could be included and also
numerous adult patients with relatively mild disease were not
included since they did not qualify our inclusion criteria.
Therefore our prevalence rates are applicable for this cohort only
and cannot be directly compared to paediatric CF cohorts or other
CF cohorts with unequal inclusion criteria [2,3]. Additionally we
analysed all parenteral antibiotics in contrast to other studies
focussing on beta-lactams [2,5,6] which may have lead to a higher⁎ Corresponding author. Tel.: +49 1637224026; fax: +49 3212 7224026.
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cohorts has already been addressed in the “Discussion” section in
our paper.
Relating to frequent exposure as a risk factor [1], we were
able to show that in our cohort for pip/taz and ceftazidime
the cumulative doses per time were significantly higher for
exposed patients with hypersensitivity than for exposed patients
without hypersensitivity to the given drug. This suggests that a
high cumulative dose in a short period may be a higher risk for
the development of hypersensitivity than the cumulative life
time exposure.
The question of tolerance induction by frequent exposure
was not evaluated in our study because many times the specific
hypersensitivity causing antibiotic drug had been put on
abstention after it had caused a reaction.
The problem of how to define drug hypersensitivity in CF for
our study was discussed extensively in our paper (“Methods” and
“Discussion” sections). We chose a clinical definition, which
seemed most important from a clinical point of view.
Thus we certainly agree that clinical history only is not a
thoroughly sufficient diagnostic measure to distinguish be-
tween immunologic phenomena and unspecific side effects.
In our patient cohort single individuals were exposed to
several kilogrammes of the same antibiotic drug; this is a
unique treatment burden and to our understanding the specific
immunology of the phenomenon in this group of patients is not
fully understood. The measure of re-exposure to the culpritll rights reserved.
356 Letter to the Editordrug is often times not feasible when dealing with severely ill
patients.
Our study's aim was to assess drug hypersensitivity in CF
including timing of reactions, risk factors and (clinical) character-
istics. The retrospective design allowed us to analyse patient's drug
exposition over a period of up to 20 years and to analyse more than
3000 treatment courses in detail making our clinical conclusions
possible. As already discussed in our paper, we agree that the term
“hypersensitivity” might be imprecise, because possibly not all of
the observed reactions might have been real allergic reactions. On
the other hand the majority of the reported symptoms in our study
[1] are listed in “WAO guidelines for anaphylaxis” [7].
Yet, we found our results interesting enough to communicate,
because they describe new aspects of a clinically relevant problem
and may contribute to other clinician's and researcher's work on
this phenomenon.
Hoping that we have been able to address sufficiently the
mentioned concerns.
Best regards,
Jobst Roehmel and Doris StaabReferences
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